All Stories

  1. LDL-Cholesterol Distance to Target: A Practical Tool for Guiding Lipid-Lowering Treatment Decisions

    Article • Atherosclerosis Plus, June 2026, Elsevier

    Dr Massimiliano Ruscica

  2. Contemporary Overview of Aortic Regurgitation in Young Individuals: Insights From Real‐Life Evidence

    Article • Journal of the American Heart Association, May 2026, Wolters Kluwer Health

    Dr Massimiliano Ruscica

  3. Plasma PCSK9 levels in children and adolescents: evidence from an Italian outpatient paediatric clinic cohort at cardio-metabolic risk.

    Article • Nutrition Metabolism and Cardiovascular Diseases, April 2026, Elsevier

    Dr Massimiliano Ruscica

  4. What Should a Clinical Cardiologist Know About Cardiogenetics?

    Article • Journal of the American Heart Association, December 2025, Wolters Kluwer Health

    Dr Massimiliano Ruscica

  5. Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice

    Article • Biomedicine & Pharmacotherapy, December 2025, Elsevier

    Dr Massimiliano Ruscica

  6. Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction

    Article • Cardiovascular Diabetology, November 2025, Springer Science + Business Media

    Dr Massimiliano Ruscica

  7. The role of the PPAR system in diabetic cardiovascular risk and beyond

    Article • Current Opinion in Endocrinology Diabetes and Obesity, November 2025, Wolters Kluwer Health

    Dr Massimiliano Ruscica

  8. From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry

    Article • Journal of Clinical Lipidology, November 2025, Elsevier

    Dr Massimiliano Ruscica

  9. Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy

    Article • Journal of Clinical Lipidology, October 2025, Elsevier

    Dr Massimiliano Ruscica

  10. Regulation of Monocyte Perilipin-2 Expression in Acute and Chronic Coronary Syndromes: Pathogenetic Implications

    Article • International Journal of Molecular Sciences, September 2025, MDPI AG

    Dr Massimiliano Ruscica

  11. Peak atrial longitudinal strain to catch atrial fibrillation in patients in sinus rhythm admitted for cerebral ischaemic events

    Article • European Journal of Preventive Cardiology, September 2025, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  12. Aspirin and lipoprotein(a): lessons from replication at scale

    Article • European Journal of Preventive Cardiology, September 2025, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  13. The role of extracellular vesicle-derived miRNA in the atherosclerotic burden

    Article • American Journal Of Pathology, September 2025, Elsevier

    Dr Massimiliano Ruscica

  14. PCSK9 genetic variants, carotid atherosclerosis and vascular remodelling

    Article • Open Heart, July 2025, BMJ

    Dr Massimiliano Ruscica

  15. Phytosterols and phytostanols in context: From physiology and pathophysiology to food supplementation and clinical practice

    Article • Pharmacological Research, April 2025, Elsevier

    Dr Massimiliano Ruscica

  16. Diagnostic Algorithm Using Multimodal Imaging for the Differential Diagnosis of Intra-Cardiac Masses

    Article • Journal of Clinical Medicine, January 2025, MDPI AG

    Dr Massimiliano Ruscica

  17. Long‐term fasting induces a remodelling of fatty acid composition in erythrocyte membranes

    Article • European Journal of Clinical Investigation, January 2025, Wiley

    Dr Massimiliano Ruscica

  18. Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy

    Article • Journal of Cystic Fibrosis, January 2025, Elsevier

    Dr Massimiliano Ruscica

  19. Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?

    Article • Atherosclerosis Plus, December 2024, Elsevier

    Dr Massimiliano Ruscica

  20. Generalized arterial calcifications in a twin recipient treated with etidronate: description of a case report within a narrative review

    Article • Archives of Medical Science, October 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  21. Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

    Article • European Journal of Clinical Investigation, October 2024, Wiley

    Dr Massimiliano Ruscica

  22. HDL cholesterol efflux capacity and cholesterol loading capacity in long-term fasting: Evidence from a prospective, single-arm interventional study in healthy individuals

    Article • Atherosclerosis, October 2024, Elsevier

    Dr Massimiliano Ruscica

  23. Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study

    Article • Cardiovascular Diabetology, August 2024, Springer Science + Business Media

    Dr Massimiliano Ruscica

  24. Concordance between Coronary Artery Computed Tomography and Invasive Coronary Angiography in a Real-World Population with Suspected Chronic Coronary Syndrome

    Article • Diagnostics, August 2024, MDPI AG

    Dr Massimiliano Ruscica

  25. Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. J. Clin. Med. 2024, 13, 943

    Article • Journal of Clinical Medicine, August 2024, MDPI AG

    Dr Massimiliano Ruscica

  26. Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction

    Article • Cancers, July 2024, MDPI AG

    Dr Massimiliano Ruscica

  27. Imaging approaches in risk stratification of patients with coronary artery disease: a narrative review

    Article • Archives of Medical Science, June 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  28. Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study

    Article • Cancers, April 2024, MDPI AG

    Dr Massimiliano Ruscica

  29. Exploring the role of epicardial adipose-tissue-derived extracellular vesicles in cardiovascular diseases

    Article • iScience, April 2024, Elsevier

    Dr Massimiliano Ruscica

  30. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

    Article • Journal of Clinical Medicine, February 2024, MDPI AG

    Dr Massimiliano Ruscica

  31. The ins and outs of lipoprotein(a) assay methods

    Article • Archives of Medical Science - Atherosclerotic Diseases, January 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  32. Extracellular vesicles in cardiomyopathies: A narrative review

    Article • Heliyon, January 2024, Elsevier

    Dr Massimiliano Ruscica

  33. Platelet Cyclic GMP Levels Are Reduced in Patients with Primary Aldosteronism

    Article • Journal of Clinical Medicine, November 2023, MDPI AG

    Dr Massimiliano Ruscica

  34. Updates in Small Interfering RNA for the Treatment of Dyslipidemias

    Article • Current Atherosclerosis Reports, October 2023, Springer Science + Business Media

    Dr Massimiliano Ruscica

  35. LDL Cholesterol Variability Impacts the Prognosis of Patients with Chronic Ischemic Heart Disease: A Real-World Italian Experience

    Article • Journal of Clinical Medicine, September 2023, MDPI AG

    Dr Massimiliano Ruscica

  36. The “Woggle” Technique for Venous Access Site Management: An Old Technique for a New Need

    Article • Journal of Clinical Medicine, September 2023, MDPI AG

    Dr Massimiliano Ruscica

  37. Right Heart Catheterization: An Antecubital Vein Approach to Reduce Fluoroscopy Time, Radiation Dose, and Guidewires Need

    Article • Journal of Clinical Medicine, August 2023, MDPI AG

    Dr Massimiliano Ruscica

  38. An association study of cyclase‐associated protein 2 and frailty

    Article • Aging Cell, August 2023, Wiley

    Dr Massimiliano Ruscica

  39. Induced myocardial ischemia in candidates to liver transplantation without evidence of heart disease

    Article • Annals of Medicine, July 2023, Taylor & Francis

    Dr Massimiliano Ruscica

  40. Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review

    Article • Frontiers in Cardiovascular Medicine, June 2023, Frontiers

    Dr Massimiliano Ruscica

  41. Protocol to evaluate the impact of murine MCT1-deficient CD8+ T cells on adipogenesis

    Article • STAR Protocols, June 2023, Elsevier

    Dr Massimiliano Ruscica

  42. Pollution from fine particulate matter and atherosclerosis: A narrative review

    Article • Environment International, May 2023, Elsevier

    Dr Massimiliano Ruscica

  43. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

    Article • Pharmacological Research, March 2023, Elsevier

    Professor Peter E. Penson, Dr Sonu Bhaskar, Professor Erkin Mirrakhimov, Prof. Maciej Banach, Dr Massimiliano Ruscica

  44. Lentilactobacillus kefiri SGL 13 and Andrographis paniculata alleviate dextran sulfate sodium induced colitis in mice

    Article • Frontiers in Nutrition, February 2023, Frontiers

    Dr Massimiliano Ruscica

  45. Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis

    Article • Frontiers in Cardiovascular Medicine, January 2023, Frontiers

    Dr Massimiliano Ruscica

  46. Long-term fasting: Multi-system adaptations in humans (GENESIS) study–A single-arm interventional trial

    Article • Frontiers in Nutrition, November 2022, Frontiers

    Dr Massimiliano Ruscica

  47. PCSK9 Inhibition and Risk of Diabetes: Should We Worry?

    Article • Current Atherosclerosis Reports, November 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  48. Role of lipoprotein(a) in plaque progression

    Article • European Heart Journal Supplements, November 2022, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  49. PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells

    Article • International Journal of Molecular Sciences, October 2022, MDPI AG

    Dr Massimiliano Ruscica

  50. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition

    Article • Expert Review of Clinical Pharmacology, October 2022, Taylor & Francis

    Dr Massimiliano Ruscica

  51. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9

    Article • Pharmacological Research, October 2022, Elsevier

    Dr Massimiliano Ruscica

  52. Omega-3 and cardiovascular prevention – Is this still a choice?

    Article • Pharmacological Research, August 2022, Elsevier

    Dr Massimiliano Ruscica

  53. Bempedoic Acid: for Whom and When

    Article • Current Atherosclerosis Reports, July 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  54. Synovial Fluid-Derived Extracellular Vesicles of Patients with Arthritides Contribute to Hippocampal Synaptic Dysfunctions and Increase with Mood Disorders Severity in Humans

    Article • Cells, July 2022, MDPI AG

    Dr Massimiliano Ruscica

  55. Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis

    Article • Journal of Clinical Medicine, July 2022, MDPI AG

    Dr Massimiliano Ruscica

  56. Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis

    Article • Frontiers in Cardiovascular Medicine, July 2022, Frontiers

    Dr Massimiliano Ruscica

  57. Monocarboxylate transporter 1 deficiency impacts CD8+ T lymphocytes proliferation and recruitment to adipose tissue during obesity

    Article • iScience, June 2022, Elsevier

    Dr Massimiliano Ruscica

  58. HDL‐mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL: Role of ABCA1 and proteasome inhibition

    Article • BioFactors, May 2022, Wiley

    Dr Massimiliano Ruscica

  59. Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice

    Article • International Journal of Molecular Sciences, May 2022, MDPI AG

    Dr Massimiliano Ruscica

  60. PCSK9 promotes arterial medial calcification

    Article • Atherosclerosis, April 2022, Elsevier

    Dr Massimiliano Ruscica

  61. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

    Article • Journal of Cachexia Sarcopenia and Muscle, March 2022, Wiley

    Professor Peter E. Penson, Dr Sonu Bhaskar, Professor Erkin Mirrakhimov, Dr Massimiliano Ruscica

  62. The Role of High-Density Lipoprotein Cholesterol in 2022

    Article • Current Atherosclerosis Reports, March 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  63. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications

    Article • Cardiovascular Research, March 2022, Oxford University Press (OUP)

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  64. Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases

    Article • Journal of Clinical Medicine, February 2022, MDPI AG

    Dr Massimiliano Ruscica

  65. Research Progress on Natural Compounds Exerting an Antidepressant Effect through Anti-inflammatory

    Article • Current Medicinal Chemistry, February 2022, Bentham Science Publishers

    Xian Jun Loh, Dr Massimiliano Ruscica

  66. PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?

    Article • Current Medicinal Chemistry, February 2022, Bentham Science Publishers

    Dr Massimiliano Ruscica

  67. Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity

    Article • Frontiers in Cardiovascular Medicine, January 2022, Frontiers

    Dr Massimiliano Ruscica

  68. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models

    Article • Cellular and Molecular Gastroenterology and Hepatology, January 2022, Elsevier

    Dr Amalia Gastaldelli, Dr Massimiliano Ruscica

  69. The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta‐analysis

    Article • BioMed Research International, January 2022, Wiley

    Dr Massimiliano Ruscica

  70. Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells

    Article • Nutrients, December 2021, MDPI AG

    Dr Massimiliano Ruscica

  71. HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study

    Article • Journal of Clinical Medicine, December 2021, MDPI AG

    Dr Massimiliano Ruscica

  72. Lipoprotein(a): Knowns, unknowns and uncertainties

    Article • Pharmacological Research, November 2021, Elsevier

    Dr Massimiliano Ruscica

  73. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

    Article • Hepatology Communications, October 2021, Wolters Kluwer Health

    Dr Massimiliano Ruscica

  74. New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran

    Article • European Heart Journal Supplements, October 2021, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  75. Cardiovascular complications of COVID-19: toward better understanding, diagnosis, monitoring and management

    Article • Expert Review of Anti-infective Therapy, August 2021, Taylor & Francis

    Dr Massimiliano Ruscica

  76. Proprotein Convertase Subtilisin/Kexin Type 9

    Article • American Journal Of Pathology, August 2021, Elsevier

    Dr Massimiliano Ruscica

  77. Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study

    Article • Biomedicines, July 2021, MDPI AG

    Dr Massimiliano Ruscica

  78. Effects of Statins on Renin–Angiotensin System

    Article • Journal of Cardiovascular Development and Disease, July 2021, MDPI AG

    Dr Massimiliano Ruscica

  79. Prognostic parameters of in‐hospital mortality in COVID‐19 patients—An Italian experience

    Article • European Journal of Clinical Investigation, June 2021, Wiley

    Dr Massimiliano Ruscica

  80. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)

    Article • Progress in Cardiovascular Diseases, June 2021, Elsevier

    Dr Sonu Bhaskar, Professor Peter E. Penson, Professor Erkin Mirrakhimov, Dr Massimiliano Ruscica

  81. Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting

    Article • Nutrients, May 2021, MDPI AG

    Dr Massimiliano Ruscica

  82. Long-term fasting improves lipoprotein-associated atherogenic risk in humans

    Article • Zeitschrift für Ernährungswissenschaft, May 2021, Springer Science + Business Media

    Dr Massimiliano Ruscica

  83. PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin

    Article • International Journal of Molecular Sciences, April 2021, MDPI AG

    Dr Massimiliano Ruscica

  84. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity

    Article • Atherosclerosis, April 2021, Elsevier

    Dr Massimiliano Ruscica

  85. Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age – An Italian cohort

    Article • Environment International, April 2021, Elsevier

    Dr Massimiliano Ruscica

  86. Lipid Lowering Drugs: Present Status and Future Developments

    Article • Current Atherosclerosis Reports, March 2021, Springer Science + Business Media

    Dr Massimiliano Ruscica

  87. Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

    Article • European Journal of Clinical Investigation, March 2021, Wiley

    Dr Massimiliano Ruscica

  88. Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease

    Article • Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, March 2021, Elsevier

    Dr Massimiliano Ruscica

  89. Cyclase-associated protein 2 (CAP2) controls MRTF-A localization and SRF activity in mouse embryonic fibroblasts

    Article • Scientific Reports, February 2021, Springer Science + Business Media

    Dr Massimiliano Ruscica

  90. Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure

    Article • Reviews in Endocrine and Metabolic Disorders, February 2021, Springer Science + Business Media

    Dr Massimiliano Ruscica

  91. Effects of PM Exposure on the Methylation of Clock Genes in A Population of Subjects with Overweight or Obesity

    Article • International Journal of Environmental Research and Public Health, January 2021, MDPI AG

    Dr Massimiliano Ruscica

  92. Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study)

    Article • Journal of Clinical Medicine, January 2021, MDPI AG

    Dr Massimiliano Ruscica

  93. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models

    Article • December 2020, Cold Spring Harbor Laboratory Press

    Dr Amalia Gastaldelli, Dr Massimiliano Ruscica

  94. Serological follow-up of SARS-CoV-2 asymptomatic subjects

    Article • Scientific Reports, November 2020, Springer Science + Business Media

    Professor Marco Buscaglia, Dr Massimiliano Ruscica

  95. Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance

    Article • Cardiovascular Diabetology, November 2020, Springer Science + Business Media

    Dr Massimiliano Ruscica

  96. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9

    Article • American Journal Of Pathology, November 2020, Elsevier

    Dr Massimiliano Ruscica

  97. Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients

    Article • Nutrition Metabolism and Cardiovascular Diseases, November 2020, Elsevier

    Dr Massimiliano Ruscica

  98. Lipoprotein(a) and PCSK9 inhibition: clinical evidence

    Article • European Heart Journal Supplements, November 2020, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  99. Cyclase-associated protein 2 (CAP2) controls MRTF-A localization and SRF activity in mouse embryonic fibroblasts

    Article • October 2020, Cold Spring Harbor Laboratory Press

    Dr Massimiliano Ruscica

  100. Impact of Phyllantus niruri and Lactobacillus amylovorus SGL 14 in a mouse model of dietary hyperoxaluria

    Article • Beneficial Microbes, October 2020, Wageningen Academic Publishers

    Dr Massimiliano Ruscica

  101. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Dr Massimiliano Ruscica

  102. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Dr Massimiliano Ruscica

  103. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study

    Article • Atherosclerosis, September 2020, Elsevier

    Dr Mauro AMATO, Dr Massimiliano Ruscica

  104. Clinical approach to the inflammatory etiology of cardiovascular diseases

    Article • Pharmacological Research, September 2020, Elsevier

    Dr Massimiliano Ruscica

  105. SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy

    Article • European Journal of Internal Medicine, August 2020, Elsevier

    Professor Marco Buscaglia, Dr Massimiliano Ruscica

  106. The efficacy of mineral corticoid receptor antagonist, canrenone, in COVID-19 patients

    Article • July 2020, Research Square

    Dr Massimiliano Ruscica

  107. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

    Article • PLoS Medicine, July 2020, PLOS

    Professor Peter E. Penson, Dr Arrigo FG CICERO, Prof. Maciej Banach, Professor Erkin Mirrakhimov, Dr Massimiliano Ruscica

  108. Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach

    Article • Journal of Clinical Medicine, July 2020, MDPI AG

    Dr Massimiliano Ruscica

  109. Inherited atherogenic dyslipidemias: are they correctly reported?

    Article • European Journal of Preventive Cardiology, June 2020, Oxford University Press (OUP)

    sabrina molinaro, Dr Massimiliano Ruscica

  110. Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition

    Article • Annals of Medicine, June 2020, Taylor & Francis

    Dr Massimiliano Ruscica

  111. PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation

    Article • Mediators of Inflammation, June 2020, Wiley

    Dr Massimiliano Ruscica

  112. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients

    Article • European Respiratory Journal, May 2020, European Respiratory Society (ERS)

    Marco Vicenzi, Dr Massimiliano Ruscica

  113. BDNF Val66Met polymorphism alters food intake and hypothalamic BDNF expression in mice

    Article • Journal of Cellular Physiology, May 2020, Wiley

    Dr Massimiliano Ruscica

  114. Naturally Occurring PCSK9 Inhibitors

    Article • Nutrients, May 2020, MDPI AG

    Dr Massimiliano Ruscica

  115. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)

    Article • Clinical Nutrition, May 2020, Elsevier

    Professor Peter E. Penson, Professor Erkin Mirrakhimov, Dr Massimiliano Ruscica

  116. Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies

    Article • European Heart Journal Supplements, March 2020, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  117. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia

    Article • Pharmacological Research, March 2020, Elsevier

    Dr Massimiliano Ruscica

  118. Acute pericarditis in a young patient with IgG immunodeficiency

    Article • Archives of Medical Science, January 2020, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  119. Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison

    Article • European Journal of Preventive Cardiology, December 2019, SAGE Publications

    Dr Massimiliano Ruscica

  120. Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring

    Article • Cell Metabolism, December 2019, Elsevier

    Dr Massimiliano Ruscica

  121. HDL therapy today: from atherosclerosis, to stent compatibility to heart failure

    Article • Annals of Medicine, November 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof Roberto Giovannoni

  122. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study

    Article • European Journal of Preventive Cardiology, October 2019, SAGE Publications

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  123. Correction to: Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

    Article • Nutrition Journal, September 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  124. Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

    Article • International Journal of Molecular Sciences, September 2019, MDPI AG

    Dr Massimiliano Ruscica

  125. A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES

    Article • Pharmacological Research, August 2019, Elsevier

    Dr Massimiliano Ruscica

  126. PCSK9 inhibition and inflammation: A narrative review

    Article • Atherosclerosis, July 2019, Elsevier

    Dr Massimiliano Ruscica

  127. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2019, Elsevier

    Dr Massimiliano Ruscica

  128. Methotrexate for Cardiovascular Risk Reduction: The Right Choice?

    Article • Angiology, June 2019, SAGE Publications

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  129. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

    Article • Cardiovascular Diabetology, June 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  130. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake

    Article • Nutrition Metabolism and Cardiovascular Diseases, June 2019, Elsevier

    Dr Massimiliano Ruscica

  131. Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

    Article • Frontiers in Aging Neuroscience, May 2019, Frontiers

    Dr Massimiliano Ruscica

  132. Can we further optimize statin therapy to increase tolerability?

    Article • Expert Opinion on Drug Discovery, May 2019, Taylor & Francis

    Dr Massimiliano Ruscica

  133. Recent advances in synthetic pharmacotherapies for dyslipidaemias

    Article • European Journal of Preventive Cardiology, May 2019, SAGE Publications

    Dr Massimiliano Ruscica

  134. PCSK9 in HIV infection: New opportunity or red herring?

    Article • Atherosclerosis, May 2019, Elsevier

    Dr Massimiliano Ruscica

  135. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

    Article • Drugs, April 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  136. Ceramides and diabetes mellitus: an update on the potential molecular relationships

    Article • Diabetic Medicine, April 2019, Wiley

    Dr Massimiliano Ruscica

  137. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

    Article • Journal of Lipid Research, March 2019, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Massimiliano Ruscica

  138. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

    Article • European Journal of Preventive Cardiology, March 2019, SAGE Publications

    Dr Massimiliano Ruscica

  139. High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2019, Endocrine Society

    Dr Massimiliano Ruscica

  140. Deciphering the role of V200A and N291S mutations leading to LPL deficiency

    Article • Atherosclerosis, March 2019, Elsevier

    Dr Massimiliano Ruscica

  141. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

    Article • Expert Opinion on Pharmacotherapy, February 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof. Maciej Banach

  142. Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

    Article • Nutrition Journal, February 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  143. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

    Article • European Journal of Preventive Cardiology, February 2019, SAGE Publications

    Dr Massimiliano Ruscica

  144. Resveratrol and cognitive decline: a clinician perspective

    Article • Archives of Medical Science, January 2019, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  145. Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis

    Article • Archives of Medical Science, January 2019, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  146. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals

    Article • European Journal of Preventive Cardiology, November 2018, SAGE Publications

    Dr Massimiliano Ruscica

  147. MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy

    Article • Trends in Pharmacological Sciences, November 2018, Elsevier

    Mohammad Mohajeri, Prof. Maciej Banach, Dr Massimiliano Ruscica

  148. Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists

    Article • Atherosclerosis, November 2018, Elsevier

    Dr Massimiliano Ruscica

  149. The effect of statin therapy on endoplasmic reticulum stress

    Article • Pharmacological Research, November 2018, Elsevier

    Dr Massimiliano Ruscica

  150. Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk

    Article • European Journal of Preventive Cardiology, October 2018, SAGE Publications

    Dr Massimiliano Ruscica

  151. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

    Article • Journal of Neurology, October 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  152. Differential Effects of Red Yeast Rice, Berberis Aristata and Morus Alba Extracts, Active Components of LopiGLIK®, on PCSK9 in HepG2 Cells

    Article • October 2018, MDPI AG

    Dr Massimiliano Ruscica

  153. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders

    Article • Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, September 2018, Elsevier

    Dr Massimiliano Ruscica

  154. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases

    Article • Journal of Cellular Physiology, August 2018, Wiley

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  155. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients

    Article • European Journal of Preventive Cardiology, July 2018, SAGE Publications

    Dr Massimiliano Ruscica

  156. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?

    Article • Annals of Medicine, July 2018, Taylor & Francis

    Dr Massimiliano Ruscica

  157. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

    Article • European Heart Journal, July 2018, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  158. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials

    Article • Journal of Clinical Lipidology, May 2018, Elsevier

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  159. PPAR Agonists and Metabolic Syndrome: An Established Role?

    Article • International Journal of Molecular Sciences, April 2018, MDPI AG

    Dr Massimiliano Ruscica

  160. Appropriateness of statin prescription in the elderly

    Article • European Journal of Internal Medicine, April 2018, Elsevier

    Dr Massimiliano Ruscica

  161. Body composition and metabolic changes during a 520-day mission simulation to Mars

    Article • Journal of Endocrinological Investigation, March 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  162. Influence of body variables in the development of metabolic syndrome—A long term follow-up study

    Article • PLOS One, February 2018, PLOS

    Dr Massimiliano Ruscica

  163. High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  164. PCSK9 induces a pro-inflammatory response in macrophages

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  165. PCSK9 as a Positive Modulator of Platelet Activation

    Article • Journal of the American College of Cardiology, February 2018, Elsevier

    Dr Massimiliano Ruscica

  166. Present therapeutic role of cholesteryl ester transfer protein inhibitors

    Article • Pharmacological Research, February 2018, Elsevier

    Dr Massimiliano Ruscica

  167. PCSK9 antagonists and inflammation

    Article • Atherosclerosis, January 2018, Elsevier

    Dr Massimiliano Ruscica

  168. Nutraceutical approaches to metabolic syndrome

    Article • Annals of Medicine, August 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  169. Bococizumab for the treatment of hypercholesterolaemia

    Article • Expert Opinion on Biological Therapy, May 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  170. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions

    Article • Nutrition Metabolism and Cardiovascular Diseases, May 2017, Elsevier

    Dr Massimiliano Ruscica

  171. PPAR-α agonists are still on the rise: an update on clinical and experimental findings

    Article • Expert Opinion on Investigational Drugs, April 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  172. Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial

    Article • Zeitschrift für Ernährungswissenschaft, October 2016, Springer Science + Business Media

    Dr Massimiliano Ruscica

  173. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

    Article • Translational Research, July 2016, Elsevier

    Dr Massimiliano Ruscica

  174. Increased circulating adiponectin in males with chronic HCV hepatitis

    Article • European Journal of Internal Medicine, October 2015, Elsevier

    Dr Massimiliano Ruscica

  175. Free and bound plasma leptin in anorexia nervosa patients during a refeeding program

    Article • Endocrine, April 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  176. Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies

    Article • Cancer Causes & Control, March 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  177. Risk identification and possible countermeasures for muscle adverse effects during statin therapy

    Article • European Journal of Internal Medicine, March 2015, Elsevier

    Dr Massimiliano Ruscica

  178. Changes in Stress Hormones and Metabolism During a 105-Day Simulated Mars Mission

    Article • Aviation Space and Environmental Medicine, August 2014, Aerospace Medical Association

    Dr Massimiliano Ruscica

  179. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance

    Article • European Journal of Clinical Investigation, June 2014, Wiley

    Luca Valenti, Dr Massimiliano Ruscica

  180. Statin therapy and related risk of new-onset type 2 diabetes mellitus

    Article • European Journal of Internal Medicine, June 2014, Elsevier

    Dr Massimiliano Ruscica

  181. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth

    Article • Molecular and Cellular Endocrinology, February 2014, Elsevier

    Dr Massimiliano Ruscica

  182. In VitroChronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Massimiliano Ruscica

  183. Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus

    Article • Journal of Clinical Lipidology, January 2014, Elsevier

    Dr Massimiliano Ruscica

  184. Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold

    Article • Bioorganic & Medicinal Chemistry, September 2013, Elsevier

    Dr Massimiliano Ruscica

  185. Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance

    Article • American Journal Of Pathology, June 2013, Elsevier

    Dr Massimiliano Ruscica

  186. Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

    Article • Current Molecular Medicine, April 2013, Bentham Science Publishers

    Dr Massimiliano Ruscica

  187. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

    Article • The Aging Male, March 2013, Taylor & Francis

    Dr Massimiliano Ruscica

  188. GC–MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Dr Fabrizio Gelmini, Dr Massimiliano Ruscica

  189. The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

    Article • BMC Gastroenterology, August 2012, Springer Science + Business Media

    Dr Massimiliano Ruscica

  190. Parthenolide Inhibits the LPS-induced Secretion of IL-6 and TNF-α and NF-κB Nuclear Translocation in BV-2 Microglia

    Article • Phytotherapy Research, February 2012, Wiley

    Dr Massimiliano Ruscica

  191. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients

    Article • Muscle & Nerve, January 2012, Wiley

    Dr Massimiliano Ruscica

  192. Prognostic Effect of Circulating Adiponectin in a Randomized 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer

    Article • Journal of Clinical Oncology, January 2012, American Society of Clinical Oncology (ASCO)

    Dr Massimiliano Ruscica

  193. Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort

    Article • Obesity Facts, January 2012, Karger Publishers

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  194. Adiponectin Interactions in Bone and Cartilage Biology and Disease

    Article • January 2012, Elsevier

    Dr Massimiliano Ruscica

  195. Corrigendum to “Regulation of prostate cancer cell proliferation by somatostatin receptor activation” [Mol. Cell. Endocrinol. 315 (1–2) (2010) 254–262]

    Article • Molecular and Cellular Endocrinology, July 2011, Elsevier

    Dr Massimiliano Ruscica

  196. Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study

    Article • International Journal of Endocrinology, January 2011, Hindawi Publishing Corporation

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  197. Adipokine actions on cartilage homeostasis

    Article • January 2011, Elsevier

    Dr Massimiliano Ruscica

  198. Erratum to “The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells” [Eur. J. Pharmacol. 641 (2010) 29-34]

    Article • European Journal of Pharmacology, January 2011, Elsevier

    Dr Massimiliano Ruscica

  199. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines

    Article • Journal of Endocrinology, September 2010, Bioscientifica

    Dr Massimiliano Ruscica

  200. The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells

    Article • European Journal of Pharmacology, September 2010, Elsevier

    Dr Massimiliano Ruscica

  201. Pharmacokinetics of orally administered melatonin in critically ill patients

    Article • Journal of Pineal Research, March 2010, Wiley

    Dr Massimiliano Ruscica

  202. Regulation of prostate cancer cell proliferation by somatostatin receptor activation

    Article • Molecular and Cellular Endocrinology, February 2010, Elsevier

    Dr Massimiliano Ruscica

  203. Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function

    Article • Current Protein and Peptide Science, December 2009, Bentham Science Publishers

    Dr Massimiliano Ruscica

  204. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients

    Article • European Journal of Neurology, October 2009, Wiley

    Dr Massimiliano Ruscica

  205. Feeding Behavior in Mammals Including Humans

    Article • Annals of the New York Academy of Sciences, April 2009, Wiley

    Dr Massimiliano Ruscica

  206. Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer

    Article • Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Dr Massimiliano Ruscica

  207. Total, free and bound leptin and thyroid function in elderly women with different body weights

    Article • Clinical Endocrinology, June 2008, Wiley

    Dr Massimiliano Ruscica

  208. Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells

    Article • Peptides, March 2008, Elsevier

    Dr Massimiliano Ruscica

  209. Relevance of the Neuropeptide Y System in the Biology of Cancer Progression

    Article • Current Topics in Medicinal Chemistry, September 2007, Bentham Science Publishers

    Dr Massimiliano Ruscica

  210. Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Ext...

    Article • Molecular Endocrinology, May 2007, Endocrine Society

    Dr Massimiliano Ruscica

  211. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas

    Article • Clinical Endocrinology, March 2007, Wiley

    Marta Korbonits, Dr Massimiliano Ruscica

  212. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer

    Article • Peptides, February 2007, Elsevier

    Dr Massimiliano Ruscica

  213. Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs

    Article • Mini-Reviews in Medicinal Chemistry, January 2007, Bentham Science Publishers

    Dr Massimiliano Ruscica

  214. Is ghrelin a signal of decreased fat-free mass in elderly subjects?

    Article • European Journal of Endocrinology, August 2006, Bioscientifica

    Dr Massimiliano Ruscica

  215. Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells

    Article • Endocrinology, March 2006, Endocrine Society

    Dr Massimiliano Ruscica

  216. Expression of Functional Ciliary Neurotrophic Factor Receptors in Immortalized Gonadotrophin-Releasing Hormone-Secreting Neurones

    Article • Journal of Neuroendocrinology, May 2005, Wiley

    Dr Massimiliano Ruscica

  217. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference

    Article • Clinical Endocrinology, February 2005, Wiley

    Dr Massimiliano Ruscica

  218. Free and bound leptin in prepubertal children with Down's syndrome and different degrees of adiposity

    Article • European Journal of Clinical Nutrition, May 2004, Springer Science + Business Media

    Dr Massimiliano Ruscica

  219. Modulatory Actions of Neuropeptide Y on Prostate Cancer Growth: Role of MAP Kinase/ERK 1/2 Activatio

    Article • Springer Science + Business Media

    Dr Massimiliano Ruscica